Critical Contrast: Capricor Therapeutics (CAPR) & Its Rivals
Capricor Therapeutics (NASDAQ: CAPR) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Capricor Therapeutics to related businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
This table compares Capricor Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Capricor Therapeutics Competitors||-5,266.10%||-428.13%||-38.73%|
Capricor Therapeutics has a beta of -3.76, indicating that its stock price is 476% less volatile than the S&P 500. Comparatively, Capricor Therapeutics’ competitors have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.
Valuation & Earnings
This table compares Capricor Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Capricor Therapeutics||$4.00 million||-$18.80 million||-2.73|
|Capricor Therapeutics Competitors||$284.30 million||$34.29 million||135.48|
Capricor Therapeutics’ competitors have higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
4.6% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 28.5% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a summary of current recommendations and price targets for Capricor Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Capricor Therapeutics Competitors||843||3191||11570||230||2.71|
Capricor Therapeutics presently has a consensus price target of $4.33, suggesting a potential upside of 140.28%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.65%. Given Capricor Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Capricor Therapeutics is more favorable than its competitors.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.